Physician profile
Varsha Singh
NPI 1275866592
$4,295.71
in general payments reported to CMS, 2019-2025
14 companies · $1,707 in 2025
The $1,707 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $140 · 2022: $614 · 2023: $886 · 2024: $949 · 2025: $1,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,115 · Travel and Lodging: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,115.09 |
| Travel and Lodging | $426.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,500.54 | 2023-2025 | Watchman Flx, Watchman Access System |
| Amgen INC. | $514.84 | 2024-2025 | Repatha |
| Alexion Pharmaceuticals, INC. | $467.79 | 2021-2023 | Soliris |
| Astrazeneca Pharmaceuticals LP | $371.81 | 2022-2024 | Wainua |
| Novo Nordisk INC | $345.07 | 2022-2025 | Ozempic |
| Medtronic, INC. | $335.74 | 2025 | Symplicity G3 |
| Janssen Pharmaceuticals, INC | $128.43 | 2024 | Xarelto |
| Sk Life Science, INC. | $124.27 | 2024 | Xcopri |
| Eisai INC. | $124.22 | 2025 | |
| Corcept Therapeutics | $115.00 | 2022 | |
| Lilly USA, LLC | $113.96 | 2025 | Mounjaro |
| Abbott Laboratories | $111.96 | 2024 | Freestyle Libre 3 |
| W. L. Gore & Associates, INC. | $28.14 | 2021-2022 | |
| Genentech USA, INC. | $13.94 | 2023 | Activase |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varsha Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.